copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Genetic Testing for Hereditary Cancer Susceptibility - AIM Specialty Health Scope This document addresses germline genetic testing for hereditary cancer predisposition syndromes It does not address somatic tumor testing (see Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies), reproductive testing for hereditary cancer syndromes (see Clinical Appropriateness Guidelines for Genetic Testing for Reproductive
Sleep | Carelon Clinical Guidelines and Pathways - AIM Specialty Health Accessing Clinical Guidelines and Cancer Treatment Pathways By clicking on the “I accept” button below, I acknowledge I accept the following terms and conditions when accessing and using the Clinical Guidelines and Cancer Treatment Pathways: Carelon Medical Benefits Management has developed proprietary Clinical Guidelines and Cancer Treatment Pathways (together with any updates, referred
ADVANCED IMAGING - AIM Specialty Health The AIM Clinical Appropriateness Guidelines (hereinafter “the AIM Clinical Appropriateness Guidelines” or the “Guidelines”) are designed to assist providers in making the most appropriate treatment decision for a specific clinical condition for an individual
Genetic Testing for Single-Gene and Multifactorial Conditions Scope This document addresses the general principles of clinical appropriateness for genetic testing, including diagnostic testing for Mendelian disorders and susceptibility testing for multifactorial conditions It also addresses genetic testing to predict risk of thrombosis See separate clinical appropriateness guidelines for more specific criteria related to reproductive genetics
Clinical Appropriateness Guidelines Molecular Testing of Solid and . . . Scope This document addresses molecular testing and gene expression profiling of solid and hematologic tumors and malignancies (including cell free tumor DNA circulating tumor cells liquid biopsy testing) for the purpose of screening surveillance, diagnosis, selecting therapeutic agents and predicting risk, prognosis, monitoring, or recurrence of cancer All tests listed in these guidelines